Nanobiotix is trading 5.63% down at $31.57 now, following a broader biotechnology selloff rather than a clearly identified company-specific negative announcement.
- On September 24, shares fell 5.05% to $33.46.
- After the September 24 close, Nanobiotix released positive clinical and operational updates, including €110.9 million in cash and runway into 2029.
- First-half net loss increased to €34.3 million.